European marketing authorisation granted for Alexion’s Kanuma™ (sebelipase alfa)
1 September 2015 | By Nick Jackson
Alexion Pharmaceuticals, Inc. has announced that the European Commission has approved Kanuma™ (sebelipase alfa) for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency...